Minerva Neurosciences Inc (NERV) Expected to Announce Earnings of -$0.35 Per Share

Equities analysts expect that Minerva Neurosciences Inc (NASDAQ:NERV) will post earnings per share of ($0.35) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences reported earnings of ($0.27) per share in the same quarter last year, which would indicate a negative year over year growth rate of 29.6%. The firm is scheduled to report its next earnings results on Thursday, August 2nd.

According to Zacks, analysts expect that Minerva Neurosciences will report full year earnings of ($1.46) per share for the current year. For the next year, analysts anticipate that the company will post earnings of ($1.50) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.04).

Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Minerva Neurosciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 16th. ValuEngine upgraded shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, May 17th. Finally, Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 15th.

Shares of NASDAQ:NERV traded down $0.35 on Friday, hitting $8.50. The stock had a trading volume of 6,582 shares, compared to its average volume of 142,906. Minerva Neurosciences has a twelve month low of $4.80 and a twelve month high of $10.15. The company has a market capitalization of $342.93 million, a PE ratio of -8.19 and a beta of 1.55.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Alps Advisors Inc. lifted its position in Minerva Neurosciences by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 51,906 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 9,021 shares in the last quarter. Highland Capital Management LP raised its holdings in Minerva Neurosciences by 4.0% during the 1st quarter. Highland Capital Management LP now owns 2,246,876 shares of the biopharmaceutical company’s stock worth $14,043,000 after purchasing an additional 86,332 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Minerva Neurosciences by 47.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 40,835 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 13,199 shares during the last quarter. Franklin Resources Inc. raised its holdings in Minerva Neurosciences by 3.6% during the 4th quarter. Franklin Resources Inc. now owns 1,235,000 shares of the biopharmaceutical company’s stock worth $7,472,000 after purchasing an additional 42,700 shares during the last quarter. Finally, Ascend Capital LLC raised its holdings in Minerva Neurosciences by 4.8% during the 4th quarter. Ascend Capital LLC now owns 819,347 shares of the biopharmaceutical company’s stock worth $4,957,000 after purchasing an additional 37,659 shares during the last quarter. Institutional investors and hedge funds own 70.52% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply